ASCO 2023: Vorasidenib Delays Tumor Growth, Improves Survival in Patients With Grade 2 Glioma With IDH Mutation
Progression-free survival was significantly longer with vorasidenib versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.